TLSI - NASDAQ

TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc.

TLSIยทNASDAQ

$3.29

+3.0%
HealthcareMedical - Devices

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$124.72M
EPS-1.8400
P/E Ratio-1.79
Earnings Date08/11/2026
TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc. Fair Value Envelope

TLSI ยท NASDAQ

Our analysis suggests that TLSI has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.29, this represents a potential HIDDEN relative to our calculated worth for TriSalus Life Sciences, Inc..

HIDDEN
Intrinsic Value
Current Price: $3.29

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$2.1B
+ Cash & Equivalents$20.4M
Firm Value-$2.0B
- Debt$34.4M
Equity Value-$2.1B
/ Shares Outstanding37,975,800B
DCF Value-$55
OVERVALUED BY 1760%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$27.7M
-$42.7M
-$65.8M
-$101.4M
-$156.2M
-$240.6M
-$370.7M
-$571.0M
-$879.6M
-$1.4B
Maintenance CapEx
-$282.8K
-$435.7K
-$671.1K
-$1.0M
-$1.6M
-$2.5M
-$3.8M
-$5.8M
-$9.0M
-$13.8M
Owner Earnings
-$28.0M
-$43.2M
-$66.5M
-$102.4M
-$157.8M
-$243.1M
-$374.5M
-$576.8M
-$888.5M
-$1.4B
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$26.0M
-$37.0M
-$52.8M
-$75.3M
-$107.4M
-$153.2M
-$218.5M
-$311.6M
-$444.5M
-$634.0M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your TLSI research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.